## TECH: Bio-Techne Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($54.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Riverbridge Partners LLC Trims Stock Position in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251222T130159 | Neutral | Relevance: 99%
- Riverbridge Partners LLC reduced its stake in Bio-Techne Corp ($TECH) by 5.1% in Q3, now holding 906,442 shares valued at approximately $50.4 million. Despite missing revenue expectations, Bio-Techne reported Q3 EPS in line with estimates and maintains a "Moderate Buy" consensus from analysts with an average price target of $71. The company also announced a quarterly dividend of $0.08 per share.

**2. Will New 3D Multiomic Workflow and Leo System Expansion Change Bio-Techne's (TECH) Narrative?**
- Source: Simply Wall Street | 20251220T032856 | Somewhat-Bullish | Relevance: 97%
- Bio-Techne's Lunaphore unit and the Wyss Center have collaborated to automate RNA and protein detection in 3D specimens, expanding Bio-Techne's spatial and proteomic platforms. The company also launched an upgraded Leo System for high-throughput protein analysis. These advancements aim to embed Bio-Techne's tools deeper into cutting-edge disease research and drug discovery, potentially reshaping its long-term growth drivers despite near-term funding challenges in biotech.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 27.1x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 27.1 |
| Current P/E | 29.9 |
| YoY Growth | 10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.6% to -0.1% (+3.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.7%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.07% (CS: 50) | Neutral |
| RSI_14 | 46.3 | Neutral |
| MACD Histogram | -0.37 | Bearish |
| vs SMA20 | 0.966x | Below |
| vs SMA50 | 0.967x | Below |
| vs SMA200 | 1.068x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $58.96
- **Stop Loss:** $54.90 (6.9% risk)
- **Target:** $63.02 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 295
- **Position Value:** $17,393.20
- **Portfolio %:** 17.39%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*